Unspecified Heartworm Prevention

Verify with FDA CVM →

69 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
69
Total Reports
5
Deaths Reported
720.0%
Death Rate

Active Ingredients

Unspecified Heartworm Prevention

Administration Routes

UnknownOralSubcutaneous

Species Affected

Dog 69

Most Affected Breeds

Retriever - Golden 7
Dog (unknown) 4
Retriever - Labrador 4
Beagle 4
Crossbred Canine/dog 4
Shih Tzu 3
Doberman Pinscher 3
Boxer (German Boxer) 3
Shepherd (unspecified) 3
Siberian Husky 3

Most Reported Reactions

Vomiting 14
Lack of efficacy (endoparasite) - heartworm 11
Diarrhoea 9
Lethargy (see also Central nervous system depression in 'Neurological') 7
Lack of efficacy - NOS 7
Weight loss 6
Underdose 5
Other abnormal test result NOS 4
Death by euthanasia 4
Panting 4
Lethargy (see also Central nervous system depression in Neurological) 4
Hyperglycaemia 3

Outcome Breakdown

Outcome Unknown
28 (40.6%)
Ongoing
22 (31.9%)
Recovered/Normal
14 (20.3%)
Euthanized
4 (5.8%)
Died
1 (1.4%)

Data Summary

Metric Value
Total adverse event reports 69
Reports involving death 5
Case-fatality rate (reported events) 720.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Unspecified Heartworm Prevention Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 69 adverse event reports referencing Unspecified Heartworm Prevention, including 5 reports in which the animal died — a 720.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Unspecified Heartworm Prevention. Reported administration routes include Unknown, Oral, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Unspecified Heartworm Prevention reports are Dog (69 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (7), Dog (unknown) (4), Retriever - Labrador (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Unspecified Heartworm Prevention are Vomiting (14), Lack of efficacy (endoparasite) - heartworm (11), Diarrhoea (9), Lethargy (see also Central nervous system depression in 'Neurological') (7). Of the 69 reports with a coded outcome, Outcome Unknown is the leading category at 40.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Unspecified Heartworm Prevention.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial